DUBLIN--(http://www.researchandmarkets.com/research/skxkm4/gallbladder) has announced the addition of Global Markets Direct's new report "Gallbladder Cancer - Pipeline Review, H2 2012" to their offering.)--Research and Markets (
“Gallbladder Cancer - Pipeline Review, H2 2012”
Global Markets Direct's, 'Gallbladder Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gallbladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gallbladder Cancer. Gallbladder Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Gallbladder Cancer.
- A review of the Gallbladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gallbladder Cancer pipeline on the basis of route of administration and molecule type.
- Latest news and deals relating to the products.
For more information visit http://www.researchandmarkets.com/research/skxkm4/gallbladder
Source: Global Markets Direct